Cargando…

Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

Detalles Bibliográficos
Autores principales:	Rodríguez-Arbolí, Eduardo, Othus, Megan, Orvain, Corentin, Zarling, Lucas C., Sandmaier, Brenda M., Milano, Filippo, Schoch, Gary, Davis, Chris, Deeg, H. Joachim, Appelbaum, Frederick R., Storb, Rainer, Walter, Roland B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827162/ https://www.ncbi.nlm.nih.gov/pubmed/36134457 http://dx.doi.org/10.3324/haematol.2022.281631

Ejemplares similares

Utility of Treatment-Related Mortality (TRM) Score to Predict Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
por: Zarling, Lucas C., et al.
Publicado: (2022)

Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia
por: Orvain, Corentin, et al.
Publicado: (2023)

Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia
por: Orvain, Corentin, et al.
Publicado: (2022)

Impact of Pre-Transplant Measurable Residual Disease on Outcome of Allogeneic Hematopoietic Cell Transplantation in Adult Monosomal Karyotype AML
por: Morsink, Linde M., et al.
Publicado: (2020)

Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
por: Morsink, Linde M., et al.
Publicado: (2020)

Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Walter, Roland B., et al.
Publicado: (2014)

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms
por: Shih, Lauren, et al.
Publicado: (2023)

Prognostic factors and outcomes of severe gastrointestinal graft-vs.-host disease after allogeneic hematopoietic cell transplantation
por: Castilla-Llorente, Cristina, et al.
Publicado: (2014)

Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy
por: Zimmerman, Zachary, et al.
Publicado: (2011)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

Analysis of Antibiotic Exposure and Development of Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
por: Rashidi, Armin, et al.
Publicado: (2023)

Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia
por: Vo, Phuong, et al.
Publicado: (2020)

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
por: Buckley, Sarah A., et al.
Publicado: (2017)

Role of Comorbidities in Optimizing Decision-Making for Allogeneic Hematopoietic Cell Transplantation
por: Sorror, Mohamed L., et al.
Publicado: (2010)

Extracorporeal photopheresis combined with pentostatin in the conditioning regimen for canine hematopoietic cell transplantation does not prevent GVHD
por: Bethge, Wolfgang, et al.
Publicado: (2014)

Extracorporeal Photopheresis in Addition to Pentostatin in Conditioning for Canine Hematopoietic Cell Transplantation: Role in Engraftment
por: Bethge, Wolfgang A., et al.
Publicado: (2010)

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant
por: Sandmaier, Brenda M., et al.
Publicado: (2017)

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
por: Maffini, Enrico, et al.
Publicado: (2019)

cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies
por: Li, Yawen, et al.
Publicado: (2018)

Cardiac Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
por: Facenda-Lorenzo, María, et al.
Publicado: (2016)

The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia
por: Maffini, Enrico, et al.
Publicado: (2022)

Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms
por: Monaco, Federico, et al.
Publicado: (2019)

The Quality of Life of Adult Survivors of Childhood Hematopoietic Cell Transplant
por: Sanders, Jean E., et al.
Publicado: (2009)

Incidence, Risk Factors, and Outcomes of Idiopathic Pneumonia Syndrome after Allogeneic Hematopoietic Cell Transplantation
por: Wenger, David S., et al.
Publicado: (2020)

Extramedullary Gastric Relapse of Acute Myeloid Leukemia After Allogenic Hematopoietic Stem Cell Transplantation
por: Hong, Ji-Yun, et al.
Publicado: (2020)

Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Antar, Ahmad I., et al.
Publicado: (2020)

Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation presenting as pericardial effusion
por: Shen, Yuyan, et al.
Publicado: (2023)

What Role Is There for Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine Hematopoietic Cell Transplantation?
por: Diaconescu, Razvan, et al.
Publicado: (2005)

Adoptive Immunotherapy Against Allogeneic Kidney Grafts in Dogs with Stable Hematopoietic Trichimerism
por: Graves, Scott S., et al.
Publicado: (2008)

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
por: Zhou, Yi, et al.
Publicado: (2016)

Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation
por: Fuchs, Mary, et al.
Publicado: (2012)

Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning
por: Guo, Zhi, et al.
Publicado: (2017)

A case of tuberculosis meningitis after allogeneic hematopoietic stem cell transplantation for relapsed Acute Myeloid Leukemia
por: Yang, Jinyoung, et al.
Publicado: (2020)

Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
por: Rautenberg, Christina, et al.
Publicado: (2020)

Minimal Residual Disease as a Predictive Factor for Relapse after Allogeneic Hematopoietic Stem Cell Transplant in Adult Patients with Acute Myeloid Leukemia in First and Second Complete Remission
por: Grubovikj, Rada M., et al.
Publicado: (2012)

Correction: Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning
por: Guo, Zhi, et al.
Publicado: (2019)

Efficacy and safety of venetoclax in combination therapy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
por: Yang, Fan, et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
por: Cooper, Jason P., et al.
Publicado: (2020)

History of hematopoietic cell transplantation: challenges and progress
por: Granot, Noa, et al.
Publicado: (2020)

Treatment of Fanconi anemia patients using fludarabine and low-dose total body irradiation followed by unrelated donor hematopoietic cell transplantation
por: Thakar, Monica S, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_vbvpbclnbt076jqr3ldon0t71f